Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1

Objective

Immune Checkpoint Inhibitors (ICPIs) have recently revolutionized the treatment and management of cancer. Yet, progress recorded and impact on long-term survival affect only a limited fraction of patients, as most of the cancer patients do not or incompletely respond to ICPIs due to primary or secondary resistance to these treatments.
NETRIS Pharma is an innovative biotech company based in Lyon. The company has developed NP137, a humanized monoclonal antibody targeting NETRIN-1, able to drive tumor growth inhibition and alleviate resistance to ICPIs, both impacts already confirmed in preclinical models.
The objective of the IMMUNONET project is to conduct a proof-of-efficacy clinical trial assessing the efficacy of NP137 to alleviate suspected resistance to ICPIs. The increased response rate to ICPIs with NP137 would have a major impact on patients having limited treatment options beyond immunotherapies and create significant growth opportunities for NETRIS.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2021-ACCELERATOROPEN-01

See all projects funded under this call

Coordinator

NETRIS PHARMA SAS
Net EU contribution
€ 2 500 000,00
Address
RUE LAENNEC 28 BATIMENT CHENEY C CENTRE LEON BERARD
69008 Lyon
France
SME
Yes
Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 8 327 233,75